SynVec team concluded a contract with a pharmaceutical company in order to identify the API of a vegetable oily extract. This project is carried out as part of collaboration between SynVec and Aquiderm.
SynVec team concluded a contract with a pharmaceutical company in order to identify the API of a vegetable oily extract. This project is carried out as part of collaboration between SynVec and Aquiderm.
SynVec team was present at the 3thd edition of the Oncology Business convention MEET2WIN organized by MATWIN which is nationwide service platform that supports the maturation of research projects in Oncology up to the pre-clinical proof of concept.
It was an opportunity for SynVec to present its competencies in vectors development for the drug delivery and its services in custom chemical synthesis.
Metformin used for treatment of type 2 diabetes, shows good results in survivalfor breast cancer patients and was promising for treatment of endometrial hyperplasia. These results were presented by researchers from the Prelman Scool of Medecine at the University of Pennsylvania at the American Society of Clinical Oncology annual meeting.
For more details please fllow this link
Depuis le mois de Mars 2016, SynVec fait désormais partie du réseau SIRIC BRIO qui regroupe les hôpitaux Universitaires (l’Institut Bergonié et CHU Bordeaux), les institutions de recherche (CNRS, INSRM), l’Université de Bordeaux ainsi que les institutions régionales régionales (Cancéropole Grad-Sud-Ouest, Réseau de Cancérologie d’Aquitaine, Groupement des Industries Pharmaceutiques et de Santé d’Aquitaine, Conseil Régional d’Aquitaine).
SynVec devient ainsi une plateforme labellisée du SIRIC BRIO ce qui permettrait aux laboratoires et Institutions faisant partie de ce réseau de pouvoir profiter du savoir faire de l’équipe de SynVec dans le domaine de la synthèse chimique à façon et de la R&D en chimie organique. Ces laboratoires pourront donc bénéficier des prestations en synthèse et R&D en chimie de SynVec afin de développer leurs programmes de recherche en Oncologie suivant les différents axes et thématiques proposés par le SIRIC. Un soutien financier est donc proposé par le SRIRIC BRIO aux laboratoires et institutions qui feront appel aux prestations SynVec dans le cadre de leurs programmes de recherche en Oncologie.
In order to show the relevance to cancer research for SynVec activies, we give you some exemples of our last projects :
SynVec worked on a project of monitoring MMPs (Matrix Metallo-Proteinases) activities allowing the design and synthesis of peptidic biochips which are able to inform about the tumor aggressiveness. The ANR (Agence Nationale de Recherche) project in which SynVec participated is a program to develop new drug delivery system (chemical vector) to target cancerous tumor angiogenesis.
In another project, modified Nucleosides, nucleolipids and phosphoramidites synthesized by SynVec are used in order to formulate new lipidic systems to target cancerous tumors by delivering therapeutic agents in the close environment of these tumors.
These projects are examples of validated applications in cancer research treated by SynVec team. Several chemical molecules which could be synthesized by our team could be potential candidates for cancer treatment. Our experiences in the chemical synthesis and chemical vectors design allow us to take part in different projects for cancer treatment. We have an expertise in the chemical biology field and interface, specially in the medical side of the chemical synthesis which could be considered as a real asset to be a privileged partner for cancer research projects.
La dégénérescence maculaire liée à l’âge (DMLA) est une maladie évolutive de la macula à déclenchement tardif qui affecte la vision centrale. Des études ont montré que certains des facteurs pouvant conduire à l’athérosclérose et aux accidents vasculaires cérébraux sont les mêmes que ceux pouvant conduire à la DMLA. Les statines se sont avérées très efficaces dans la prévention des accidents vasculaires cérébraux, de sorte qu’il est possible qu’elles puissent aussi protéger de la DMLA. Un certain nombre d’études observationnelles avaient examiné la relation entre la DMLA et l’utilisation de statines, mais les résultats étaient contradictoires.
Cette revue systématique a identifié un essai contrôlé randomisé achevé et un en cours. Pour ce qui concerne l’essai achevé, dans lequel 30 patients avaient reçu quotidiennement pendant trois mois soit 20 mg de simvastatine soit un placebo, les analyses n’ont pas montré de différence statistiquement significative dans l’acuité visuelle à la fin du traitement ou 45 jours après l’achèvement du traitement. Pour l’essai en cours, les analyses préliminaires après 12 mois de traitement n’ont pas montré de différence statistiquement significative entre 40 mg quotidiens de simvastatine et un placebo, au niveau de l’acuité visuelle, de l’accumulation des drusens ou de la fonction visuelle. Vues la petite taille de l’essai terminé et la courte durée du traitement et de la période de suivi, aucune conclusion concernant les effets des statines sur l’apparition ou la progression de la DMLA ne peut être tirée à ce jour. Nous mettrons à jour cette revue lorsque les données de l’essai en cours seront disponibles.
Souce link : http://www.cochrane.org/fr/CD006927/les-statines-pour-retarder-lapparition-et-la-progression-de-la-degenerescence-maculaire-liee-a-lage
C’est une découverte prometteuse de chercheurs du Centre de recherche sur le cancer de Toulouse d’un métabolite suppresseur de tumeur, issu du métabolisme combiné du cholestérol et de l’histamine -une molécule naturellement produite par le corps (ou apportée par l’alimentation). Ce métabolite humain rare pourrait donner lieu au développement de nouveaux traitements contre le cancer, selon ces travaux, présentés dans la revue Current Medicinal Chemistry.
Les chercheurs de Toulouse, Sandrine Silvente-Poirot, Florence Dalenc et Marc Poirot expliquent le processus qui les a conduits à découvrir ce métabolite et décrivent ses propriétés pharmacologiques : l’équipe identifie ici une enzyme impliquée dans le métabolisme du cholestérol -5,6-époxyde, cible du Tamoxifène* (*hormonothérapie qui va bloquer l’action des hormones oestrogènes sur les cellules cancéreuses) : précisément, le Tamoxifène induit une production de 5,6-CE dans les cellules cancéreuses mammaires. Les chercheurs font donc l’hypothèse d’une nouvelle voie métabolique prometteuse, à partir de la transformation métabolique du cholestérol -5,6-époxyde. Ils montrent que le métabolisme du cholestérol » 5,6α-EC » avec l’histamine va produire cette molécule, la dendrogénine A (DDA).
Les promesses de la dendrogénine A : DDA présente une forte activité pour induire une activité de différenciation cellulaire à faible dose ce qui suggère son caractère endogène. Les chercheurs constatent ensuite que les niveaux de DDA sont fortement diminués dans les tumeurs, suggérant l’implication de DDA dans les cancers.
» Plus fort « , combler cette carence en DDA dans des tumeurs chez des souris modèles, induit un effet anticancéreux puissant et à de faibles doses, ce qui semble confirmer la fonction physiologique de DDA dans le maintien de l’intégrité cellulaire et la différenciation.
DDA, premier alcaloïde stéroïdien trouvé à ce jour chez les mammifères : sa découverte révèle ainsi l’existence d’une nouvelle voie métabolique chez les mammifères au carrefour du cholestérol et le métabolisme de l’histamine qui conduit à la production d’un gène suppresseur de tumeur métabolique.
On l’aura compris, cette étude un peu complexe, aboutit sur un composé anticancéreux puissant et prometteur.
Source: Current Medicinal Chemistry Jan, 2016 DOI: 10.2174/0929867322666150716114912 Dendrogenin A: A Mammalian Metabolite of Cholesterol with Tumor Suppressor and Neurostimulating Properties (Visuel@Bentham Science Publishers & Dr. Marc Poirot)
link : http://blog.santelog.com/2016/01/18/cancer-decouverte-dun-suppresseur-de-tumeur-puissant-et-prometteur-current-medicinal-chemistry/
In a quest to stay healthy, many people are seeking natural ways to prevent neurodegenerative diseases. Recent studies show that pomegranate extract, which is a rich source of disease-fighting polyphenols, can help protect against the development of Alzheimer’s disease. But researchers weren’t sure which molecules to thank. A team reports in ACS Chemical Neuroscience that the responsible compounds may be urolithins, which are made when gut bacteria break down the polyphenols in the extract.
Alzheimer’s disease is associated with ß-amyloid (Aß) fibrillation, a process in which amyloid proteins in the brain form clumps. To fight the formation of these fibrils, however, a molecule would have to cross the blood-brain barrier — a series of cell junctions that prevent certain substances from entering the brain. In previous work, the researchers showed that a pomegranate extract has anti-Alzheimer’s effects in animals, but they did not identify the compounds responsible. Navindra Seeram and colleagues wanted to investigate which compounds in pomegranate could both pass through the blood-brain barrier and prevent Aß fibrils from forming.
The team isolated and identified 21 compounds — mostly polyphenols — from the pomegranate extract. Computational studies found that polyphenols could not cross the blood-brain barrier, but that urolithins could. Urolithins are anti-inflammatory and neuroprotective compounds that are formed when ellagitannins, a type of polyphenol, are metabolized by gut bacteria. The researchers then showed that urolithins reduced Aß fibrillation levels in vitro. Additionally, these compounds increased the lifespan of an Alzheimer’s roundworm model. They say further tests are needed to determine whether the protective effects of these compounds could ultimately help prevent or treat Alzheimer’s in humans.
Souce link : http://neurosciencenews.com/pomegranate-gut-bacteria-alzheimers-3252/
Original Research: Abstract for “Pomegranate’s Neuroprotective Effects against Alzheimer’s Disease Are Mediated by Urolithins, Its Ellagitannin-Gut Microbial Derived Metabolites” by Tao Yuan, Hang Ma, Weixi Liu, Daniel B. Niesen, Nishan Shah, Rebecca Crews, Kenneth N. Rose, Dhiraj A. Vattem, and Navindra P. Seeram in ACS Chemical Neuroscience. Published online November 11 2015doi:10.1021/acschemneuro.5b00260
A new drug combination may be effective in treating men with metastatic prostate cancer. Preliminary results of this new approach are encouraging and have led to an ongoing international study being conducted in 196 hospitals worldwide.
“We hope to find a well-tolerated and effective treatment to slow the progression of prostate cancer in men with advanced prostate cancer. The approach combines several drugs and attacks the cancer on several fronts,” said Dr. Fred Saad, researcher at the University of Montreal Hospital Research Centre (CRCHUM) and principal investigator of the study.
Antonio Paris, 59, is one of the patients participating in the CRCHUM. “Since I started the new treatment 14 months ago, my cancer first remitted and now is stable,” he said.
With early detection, prostate cancer is treatable. The vast majority of men recover. But it’s a different story for castration-resistant metastatic prostate cancer. In this most advanced form of the disease, the cancer progresses despite treatment options which include radiation therapy, hormone administration, and even removal of the prostate or testicles. Few options are available to halt the cancer that has spread outside the prostate and is resistant to hormone treatment. Since 2011, abiraterone acetate, sold under the name Zytiga®, has been administered orally in addition to standard hormone treatment. It blocks the production of testosterone, the male hormone, which acts as a fuel for cancerous tumours. “This treatment and other recent advances have extended the survival rates of men with the most advanced stages of prostate cancer while improving their quality of life. Life expectancy has increased from 18 months on average in 2004 to three years in 2015.
In a Phase 1 clinical trial, researchers tested the safety of a preliminary combination treatment of abiraterone acetate and another drug not yet approved for market, JNJ-56021927. Antonio Paris participated in this initial research phase. “I take 14 pills a day, and it’s going very well. I have the sweats and I’m tired a bit, but it doesn’t stop me from doing all kinds of activities and even renovations,” he said.
“Our trial conducted on forty patients indicate that this treatment is safe. The combined drugs are well tolerated and the treatment appears effective,” said Dr. Saad. Given these encouraging results, the U.S. Food and Drug Administration and Health Canada authorized the start of a Phase 3 clinical study. The trial is designed to compare the efficacy of abiraterone acetate (1000 mg) and a placebo versus treatment combining abiraterone acetate (1000 mg) and JNJ-56021927 (240 mg). In both groups, patients also receive small doses of prednisone to help the treatment and reduce the side effects of abiraterone acetate. Dr. Saad co-directs this randomized, double-blind trial involving 960 patients worldwide.
The findings of this international study will not be known for about another three years. The future treatment will therefore not be marketed for several years. But the researchers are enthusiastic. They hope this first combination treatment will successfully delay progression of the disease and prolong life. And above all, that it will improve the quality of life of patients with this devastating disease.
A team of scientists, including several from the U.S. Department of Energy’s Argonne National Laboratory, have determined the structures of several important tuberculosis enzymes, which could lead to new drugs for the disease.
Tuberculosis, caused by Mycobacterium tuberculosis bacteria, has proved incredibly stubborn even in the age of powerful antibiotics, infecting about one third of all people worldwide. Treatment can take up to nine months. It has stealth properties that protect it from antibiotics; it can hide inside human cells, avoiding the body’s immune system while it waits for the opportune moment to multiply; and it’s very resourceful at acquiring resistance.
“What we have now may not work in a few years,” said Andrzej Joachimiak, an Argonne Distinguished Fellow, head of the Structural Biology Center, co-principal investigator at the Center for Structural Genomics of Infectious Diseases and a corresponding author on the new study.
In order to make new drugs, researchers need to search through the thousands of proteins in the bacterial world to find one that does something so important the bacterium can’t live without it—and then make a little block to match.
One such entry point might be IMPDH (inosine-5?-monophosphate dehydrogenase), which is part of a cellular process that controls the making of guanine nucleotides, one of the building blocks for DNA and RNA. It’s so essential that virtually all living organisms, including human and bacterial pathogens, have versions of it.
“What we discovered earlier this year is that the human and bacterial versions bind molecules differently,” Joachimiak said. “This is very important for finding a molecule to build a drug around—you don’t want to inhibit a human enzyme, just the pathogen one.”
Researchers have been interested in the mycobacterium IMPDH enzyme as a drug target for years, Joachimiak said, but haven’t been able to produce it well enough to study it.
The team observed that one part of the enzyme’s structure was particularly wobbly, so they engineered a version without it using resources at the Advanced Protein Characterization Facility and then then determined the structure employing synchrotron protein crystallography at the Advanced Photon Source, a DOE Office of Science User Facility (both at Argonne).
The modified version functions very similarly to the original, Joachimiak said, but is much easier to purify and crystallize for study.
Brandeis University professor Lizbeth Hedstrom and University of Minnesota professor Courtney Aldrich, two of the study’s other research collaborators, had identified several inhibitor molecules that bind to IMPDH, and thus might be a starting point for a drug—but they couldn’t be imaged while interacting with the enzyme. The new engineered enzyme allowed them to capture the structures of Hedstrom’s and Aldrich’s inhibitors in action, locked with IMPDH.
Helena Boshoff at the National Institute of Allergies and Infectious Diseases performed complementary studies showing that these inhibitors do in fact efficiently block mycobacterium growth.
The new structures were deposited into the Protein Data Bank for continued study
More information: Magdalena Makowska-Grzyska et al. Mycobacterium tuberculosis IMPDH in Complexes with Substrates, Products and Antitubercular Compounds, PLOS ONE (2015). DOI: 10.1371/journal.pone.0138976
Ce petit essai clinique de l’Université de Georgetown dont les résultats viennent d’être présentés à Neuroscience 2015, la réunion annuelle de la Society for Neuroscience (Chicago), révèle le nilotinib (Tasigna®), un médicament indiqué dans le traitement de la leucémie myéloïde chronique (LMC) comme efficace pour améliorer la cognition et la motricité chez certains patients parkinsoniens. Alors que le médicament est déjà approuvé, ces données ouvrent un espoir à court terme pour les patients atteints et leur famille.
C’est un petit essai de phase I, d’une durée de 6 mois, de doses croissantes de nilotinib (150 à 300 mg par jour), mené sur 11 patients atteints de la maladie de Parkinson, montre sur 10 d’entre eux des améliorations cliniques significatives :
– l’efficacité sur la cognition, la motricité et l’amélioration d’autres fonctions (constipation) est observée chez la majorité des patients et de manière » spectaculaire » : ainsi, un patient, en fauteuil roulant s’est montré capable de remarcher. 3 autres patients ont retrouvé une fluidité de la parole. Le taux de chutes est également réduit.
Ces améliorations des symptômes sont corroborées par l’observation d’évolutions positives dans le liquide céphalo-rachidien (LCR) de biomarqueurs connus de la maladie de Parkinson (α-synucléine, bêta-amyloïde et tau, dopamine).
Le Dr Charbel Moussa, directeur du Laboratoire sur la démence et la maladie de Parkinson de Georgetown à l’origine de cette découverte des bénéfices du nilotinib dans le traitement des maladies neurodégénératives suggère que le traitement semble pouvoir inverser à un degré dépendant du stade de la maladie, le déclin cognitif et moteur chez les patients atteints de maladies neurodégénératives.
De premiers signaux très prometteurs: S’il reste certes à mener des études plus vastes, avec groupe témoin, avant confirmer ces effets positifs, cependant les premiers signaux sont prometteurs, à plus d’un titre :
– En particulier, le traitement induit une augmentation de la production de dopamine chez de nombreux patients, permettant, dans certains cas de réduire leurs doses de L-dopa ou d’autres médicaments dopaminergiques.
– De plus, cette utilisation du nilotinib, à des doses beaucoup plus faibles que pour le traitement de la LMC n’entraine pas d’effets secondaires sévères.
– le médicament pénètre dans la barrière hémato-encéphalique en quantités supérieures aux médicaments dopaminergiques.
– Enfin, ici à » petite » dose, le nilotinib induit une autophagie cellulaire suffisante pour » nettoyer » les cellules du cerveau sans entraîner leur mort (comme c’est en revanche le cas, pour les cellules cancéreuses, lorsqu’il est utilisé à plus fortes doses dans le traitement de la LMC).
Seul bémol, c’est un traitement cher, soit plus de 10.000 $/ mois pour 800 mg par jour (dose pour LMC). La dose utilisée dans cette étude était de 150 et 300 mg par jour.
Etude / Neuroscience 2015 17-Oct-2015 Communiqué Cancer drug improved cognition and motor skills in small Parkinson’s clinical trial (Visuel@ Georgetown University)
What do tumor cells, the placenta and malaria all have in common? A sugar, apparently, but not just any old sugar: one that might pave way for the development of broad treatment effective against a range of cancers.
This discovery, published in Cancer Cell, is the result of a collaboration between the University of British Columbia, the University of Copenhagen and the BC Cancer Agency, and finally offers an explanation for a curious observation that scientists long struggled to explain. Pregnant women, it turns out, are particularly susceptible to malaria. And it was the search for an explanation that ultimately led to this important find.
The researchers discovered that the malaria parasite, Plasmodium falciparum, engineers infected red blood cells to produce and present a malarial protein called VAR2CSA, which sticks to a type of sugar exclusively found in the placenta. Or so they thought. Tumor cells, it was revealed, also express a virtually identical sugar molecule. Both molecules are a type of chondroitin sulfate. That wasn’t a tremendous shock, though, because these two distinct tissues do share similarities: they both grow very rapidly and in an invasive manner.
“Scientists have spent decades trying to find biochemical similarities between placenta tissue and cancer, but we just didn’t have the technology to find it,” study coauthor and project leader Mads Daugaard said in a statement. “When my colleagues discovered how malaria uses VAR2CSA to embed itself in the placenta, we immediately saw its potential to deliver cancer drugs in a precise, controlled way to tumors.”
To examine this idea, the researchers generated VAR2CSA in the lab and attached one of two toxic molecules to it before testing out the novel compound on a bounty of both normal and tumor cell lines representing various different cancers. Encouragingly, the drug displayed specificity for the cancer cells only, attaching to them and delivering a deadly toxic blow after being absorbed. In fact, the compound was so potent that it successfully targeted and killed 95% of the cancer cell lines investigated, which included brain, blood, prostate and breast.
But sticking your finger in a tissue culture dish will quite easily kill cells, so the researchers took their drug one step further and tested it out on mice that were implanted with three different human cancers, all of which responded. In those with non-Hodgkin’s lymphoma, the tumors shrunk to around a quarter of the size of those in the untreated group, and two out of six treated mice with prostate cancer went into remission just one month after receiving the drug. Last but not least, five out of six mice with metastatic (tumors that have spread) breast cancer were cured.
“There is some irony that a disease as destructive as malaria might be exploited to treat another dreaded disease,” lead author Ali Salanti said in a statement.
Of course, we can’t get overexcited about animal trials, but the results are nonetheless encouraging. And two companies are already working towards developing a compound suitable for trials in humans, but that will take at least three to four years.
Source link : http://www.iflscience.com/health-and-medicine/malaria-protein-could-give-us-broad-cancer-treatment
Study raises question about whether proteins implicated in the disease are capable of spreading through medical procedures
Prions are the misshapen proteins that replicate by inducing normal proteins to misfold and aggregate in the brain, leading to rare diseases such as mad cow and kuru. In recent years, scientists have discovered that similar processes of protein misfolding are at work in many neurodegenerative disorders, including Alzheimer’s, Parkinson’s and Lou Gehrig’s disease. Now, a study in Nature reveals the first evidence for human-to-human transmission of the misfolded proteins that underlie the pathology of Alzheimer’s disease
The new findings draw upon earlier research conducted on a prion disease. Between 1958 and 1985, a number of individuals with short stature received shots of human growth hormone extracted from the pituitary glands of cadavers. The gland is a pea-sized structure that sits at the base of the brain. Some of these samples were contaminated with prions that caused certain patients to develop Creutzfeldt-Jakob disease (CJD), a rare and fatal brain disorder. Treatments ceased once these reports came to light, but by that time an estimated 30,000 people had already received the injections. As of 2012, researchers have identified 450 cases of CJD worldwide that are the result of these growth hormone injections and other medical procedures, including neurosurgery and transplants.
Misfolding of the amyloid-beta proteins is a hallmark of Alzheimer’s. Previous studies have shown that minute amounts of amyloid-beta injected into animals such as mice or monkeys act as seeds that initiate a chain reaction of protein misfolding that resembles the pathology of Alzheimer’s. However, until now, no studies have found evidence that this process occurs in humans.
To explore the question of human transmission, John Collinge, a neuroscientist at University College London and his colleagues, conducted an autopsy study of eight patients who died from CJD after treatment with cadaver-derived growth factor. To their surprise, they found that six of the brains had the amyloid-beta pathology found in Alzheimer’s patients, and four exhibited some degree of cerebral amyloid angiopathy, in which amyloid deposits build up on the walls of blood vessels in the brain.
The patients were between the ages of 36 and 51—typically too young to exhibit Alzheimer’s pathology—and none of the individuals bore genetic mutations associated with early onset of the disease. All evidence pointed toward one possibility: Like prions, amyloid-beta seeds were in the growth hormone injections and infected these individuals. Although none of the brains showed any other Alzheimer’s disease markers, such as buildup of another misfolded protein called tau, the researchers suggest that had the patients not died young, they would have developed the disease later in life.
The research may be a first step toward answering the question of whether human-to-human transmission of pathological proteins is possible. “This is an observational study,” Collinge says. “We’re simply describing what we see in these patients and we are trying to explain that.” This study alone, he says, does not suffice to prove that the Alzheimer’s disease process can be induced in one individual through contact with another’s brain tissue. In a follow-up study, the researchers are hoping to obtain archived batches of the cadaver-derived human growth hormone to look for the presence of telltale, small clusters of amyloid–beta.
By Diana Kwon
source link : http://www.scientificamerican.com/article/evidence-for-person-to-person-transmission-of-alzheimer-s-pathology/
Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have developed a drug delivery technology that consists of an elastic patch that can be applied to the skin and will release drugs whenever the patch is stretched.
For example, if applied to the elbow, the patch would release a drug when the elbow bends and stretches the patch.
“This could be used to release painkillers whenever a patient with arthritic knees goes for a walk, or to release antibacterial drugs gradually as people move around over the course of a day,” says Zhen Gu, co-senior author of a paper describing the work and an assistant professor in the joint biomedical engineering program at NC State and UNC-Chapel Hill.
The technology consists of an elastic film that is studded with biocompatible microcapsules. These microcapsules, in turn, are packed with nanoparticles that can be filled with drugs.
Here’s how it works: The microcapsules stick halfway out of the film, on the side of the film that touches a patient’s skin. The drugs leak slowly out of the nanoparticles and are stored in the microcapsules. When the elastic film is stretched, it also stretches the microcapsules – enlarging the surface area of the microcapsule and effectively squeezing some of the stored drug out onto the patient’s skin, where it can be absorbed.
“When the microcapsule is stretched from left to right, it is also compressed from bottom to top,” says Yong Zhu, co-senior author of the paper and an associate professor of mechanical and aerospace engineering at NC State. “That compression helps push the drug out of the microcapsule.”
After being stretched, the microcapsule is “re-charged” by the drugs that continue to leak out of the nanoparticles.
“This can be used to apply drugs directly to sites on the skin, such as applying anti-cancer medications to melanomas or applying growth factors and antibiotics for wound healing,” says Jin Di, co-lead author and a Ph.D student in Gu’s lab.
The researchers also incorporated microneedles into the system, applying them on top of the microcapsules. In this configuration, the drugs can be squeezed through the microneedles. The microneedles are small enough to be painless, but large enough to allow drugs to diffuse into the bloodstream through tiny capillaries underneath the skin. “This expands the range of drugs that can be applied using the technology,” says Shanshan Yao, co-lead author and a Ph.D student in Zhu’s lab.
“We’re now exploring how this tool can be used to apply drugs efficiently and effectively to burn patients, and we plan to look at how this could be used for pain relief as well,” Gu says.
“The materials are relatively inexpensive, and the manufacturing process is fairly straightforward, so we’re optimistic that this could be scaled up in a cost-effective way,” Zhu says.
The paper, “Stretch-Triggered Drug Delivery from Wearable Elastomers Containing Therapeutic Depots,” is published online in the journal ACS Nano. Co-authors include Yanqi Ye and Jicheng Yu of the joint biomedical engineering program, and Zheng Cui and Tushar Ghosh of NC State.
The work was supported by the American Diabetes Association, a pilot grant from UNC Chapel Hill’s NC TraCS Institute, and by the National Science Foundation through the ASSIST Engineering Research Center at NC State.
Source link : https://news.ncsu.edu/2015/08/technology-releases-drugs-when-stretched/
We’re always hearing about how 3D printing will be capable of delivering major medical advancements in the near future, but this time the big change is right on our doorstep: the US Food and Drug Administration (FDA) has just approved the first 3D-printed drug, potentially heralding a turning point in the way that modern medications are manufactured and taken.
Spritam, made by US-based pharmaceuticals company Aprecia, is an oral formulation of levetiracetam, which is used to control seizures in people who have epilepsy. This new 3D-printed incarnation of the drug is manufactured by a proprietary system developed by Aprecia called ‘ZipDose’, which stacks layer upon layer of powdered medication with liquid to create a new kind of highly disintegratable tablet
The technique ensures that the 3D printing isn’t just for marketing buzz – although that weren’t hurt Aprecia either. The idea is that the tiny tablet and rapid delivery of levetiracetam will make Spritam easier for people to take by encouraging quick, consistent and regular use.
While all ongoing medications should be taken as prescribed – which usually calls for following a regular dosage schedule – the consequences of forgetting to take or otherwise skipping epilepsy medication can be more severe than missing medications for other illnesses. Aprecia cites studies that have shown poor adherence to epilepsy medication can result in experiencing breakthrough seizures. In one case, 71 percent of patients surveyed admitted to having forgotten, missed, or skipped a dose of seizure medication, with almost half reporting a seizure resulting from the lapse.
The ZipDose system is designed to get around these sorts of issues by providing a quicker delivery form: a high dose of medication in a rapidly disintegrating tablet. It does this by depositing liquid droplets of an aqueous fluid on each thin layer of powdered medication. When the 3D-printed tablet comes into contact with a small amount of water, the bonds holding the pill together will rapidly break down, enabling a patient to consume as much as 1,000 mg of a medicated dose with just a single sip of water. It’s not a magic bullet ensuring people take their meds, but anything that makes pills easier to swallow can’t hurt patients’ prospects.
“By combining 3DP technology with a highly-prescribed epilepsy treatment, Spritam is designed to fill a need for patients who struggle with their current medication experience,” said Don Wetherhold, Aprecia’s CEO, in a statement. “This is the first in a line of central nervous system products Aprecia plans to introduce as part of our commitment to transform the way patients experience taking medication.”
Source link : http://www.sciencealert.com/the-fda-has-just-approved-the-first-3d-printed-drug
In the battle against cancer, which kills nearly 8 million people worldwide each year, doctors have in their arsenal many powerful weapons, including various forms of chemotherapy and radiation. What they lack, however, is good reconnaissance—a reliable way to obtain real-time data about how well a particular therapy is working for any given patient.
Magnetic resonance imaging and other scanning technologies can indicate the size of a tumor, while the most detailed information about how well a treatment is working comes from pathologists’ examinations of tissue taken in biopsies. Yet these methods offer only snapshots of tumor response, and the invasive nature of biopsies makes them a risky procedure that clinicians try to minimize.
Now, researchers at MIT’s Koch Institute for Integrative Cancer Research are closing that information gap by developing a tiny biochemical sensor that can be implanted in cancerous tissue during the initial biopsy. The sensor then wirelessly sends data about telltale biomarkers to an external “reader” device, allowing doctors to better monitor a patient’s progress and adjust dosages or switch therapies accordingly. Making cancer treatments more targeted and precise would boost their efficacy while reducing patients’ exposure to serious side effects.
“We wanted to make a device that would give us a chemical signal about what’s happening in the tumor,” says Michael Cima, the David H. Koch (1962) Professor in Engineering in the Department of Materials Science and Engineering and a Koch Institute investigator who oversaw the sensor’s development. “Rather than waiting months to see if the tumor is shrinking, you could get an early read to see if you’re moving in the right direction.”
Two MIT doctoral students in Cima’s lab worked with him on the sensor project: Vincent Liu, now a postdoc at MIT, and Christophoros Vassiliou, now a postdoc at the University of California at Berkeley. Their research is featured in a paper in the journal Lab on a Chip that has been published online.
Measurements without MRI
The sensors developed by Cima’s team provide real-time, on-demand data concerning two biomarkers linked to a tumor’s response to treatment: pH and dissolved oxygen.
As Cima explains, when cancerous tissue is under assault from chemotherapy agents, it becomes more acidic. “Many times, you can see the response chemically before you see a tumor actually shrink,” Cima says. In fact, some therapies will trigger an immune system reaction, and the inflammation will make the tumor appear to be growing, even while the therapy is effective.
Physicists are using a technique reminiscent of a classic video game to observe DNA on the nanoscale. They call it “single-molecule Tetris.” The approach consists of a device filled with tiny channels and cavities that DNA molecules can move in and out of, resulting in some of the familiar Tetris shapes, like the “L,” the square, and the zigzag (illustrated above: a DNA molecule, in red, occupies four cavities in a zigzag). As the chainlike molecules bend or jump into different shapes, researchers use that information to measure two very specific characteristics of DNA molecules—the width and the confined free energy, or entropy of the molecule. Here, entropy relates to how many ways the energy of the molecule can be arranged. Physically, it correlates to the different shapes the molecule can take while maintaining the same distance between its two ends. Scientists collected data, published this month in Macromolecules, on these parameters to show the precise conditions under which DNA can be trapped in the cavities. It’s a feat that’s extremely difficult to do on such a minute scale, but thanks to single-molecule Tetris, these physicists now have results that could help biologists improve genome sequencing and tease out valuable genetic information from these tiny, confined bits of DNA.
Source link : http://news.sciencemag.org/chemistry/2015/07/single-molecule-tetris-allows-scientists-observe-dna-nanoscale
The Phase IIIb CONSIGN study has confirmed the benefit of regorafenib in patients with previously treated metastatic colorectal cancer (mCRC).
Researchers announced the results at the European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2015 in Barcelona
The safety profile and progression free survival were similar to Phase III trial results.
CONSIGN was a prospective, observational study that was initiated to allow patients with mCRC access to regorafenib before marketing authorisation and to assess safety, which was the primary endpoint. The randomised Phase III CORRECT trial previously showed that regorafenib significantly improves survival in patients with pre-treated mCRC and led to regulatory approval.
“We began CONSIGN at the suggestion of the authorities and to fulfil the wishes of patients and doctors for a larger expanded access,” said lead study author Prof Eric Van Cutsem from University Hospitals Leuven, Belgium. “Today we report on safety and progression-free survival in a large cohort of patients that more closely resembles daily clinical practice than the pivotal registration trial.”
CONSIGN included more than 2,800 patients at 188 sites in 25 countries who received regorafenib for a median of 2.5 months. Grade >3 adverse events occurred in 80% of patients. The estimated progression-free survival was 2.7 months and was similar across KRAS wild type and mutant subgroups.
Need to establish guidelines on the management of adverse events to make regorafenib more tolerable for patients
Van Cutsem said, “This study in a real world population of patients with pre-treated mCRC shows a similar safety profile and progression-free survival with regorafenib as shown in the randomised CORRECT trial. The findings add to our knowledge of how to select patients and how to manage toxicities. We need to establish clear guidelines on the management of adverse events to make taking the drug more tolerable for patients.”
Commenting on the data, Dr Dirk Arnold, ESMO spokesperson, director of the Department of Medical Oncology, Klinik für Tumorbiologie in Freiburg, Germany, said, “CONSIGN confirms the efficacy and safety data of the randomised Phase III CORRECT and CONCUR trials. The merit of CONSIGN is that it translates Phase III data into the clinical routine since patients had similar characteristics and pre-treatment to what we see in daily practice.”
The adverse events reported in CONSIGN were within the scope of expectation and comparable to the CORRECT trial, added Arnold. “There were no surprising findings in terms of toxicity,” he said. “All of the adverse events were quite class specific and also likely manageable.”
He added, “CONSIGN depicts what we would expect from an observational trial in this setting. It shows that we have further treatment options for mCRC patients pre-treated with chemotherapy, and that this comes at the cost of a specific, but manageable toxicity profile.”
Regarding the next step in this research area, Arnold said, “Biomarkers have been extensively investigated in the randomised trials but until now nothing has been found that would allow prediction of the benefit of regorafenib for a specific group of patients. I would suggest having a further look at the data in the observational CONSIGN study to see if there are clinical characteristics that identify patients who could benefit more or less from this treatment.”
Whether artificial or natural, nanoparticles are increasingly used in everyday life (in electronics, paints, cosmetics, pharmaceuticals, and in information technology). But pollution issues can arise, particularly in water in which nanometer-sized particles may become micropollutants and endocrine disruptors for aquatic fauna. And until now, there was no decontamination system for this environment.
Researchers from the ChemBioMed* team at the Inserm (French Institute of Health and Medical Research)ARN (Artificial and Natural Regulation) laboratory, along with biologists from the IMBE (Mediterranean Institute of Marine and Terrestrial Biodiversity and Ecology), have created an artificial supramolecular hydrogel capable of trapping nanoparticles. A gel is a material consisting of a liquid (water in this case) trapped in a molecular network that makes it solid (examples of this include gelatin, contact lenses, etc.). The nanostructure of this gel can trap gold and titanium particles less than 50 nanometers in diameter. This study, financed by the ANR (French National Research Agency) has just been the subject of a publication in the review Chemical Communications (ChemCom), the filing of a patent, and a paper presented at an international conference in Madrid.
Philippe Barthélémy, a professor at the University of Bordeaux who is the team director, explained that the problem with this material is its price. Scientists have continued their studies in order to find a more natural material. It was Alain Thiéry, a professor at the IMBE, along with his colleague Fabien Lombard, a researcher at the Villefranche-sur-Mer Marine Research Station, who thought of jellyfish as they had noted their nanoparticle bioaccumulating properties. Studying them more closely, the researchers discovered that it was the slime secreted by the jellyfish when they are stressed, during reproduction and even at the time of their death, that was able to trap nanoparticles with quite surprising results.
This research is interesting in ecological terms for two reasons: both when it comes to reducing the toxic and environmental impact of the nanoparticles and in combating an increase in the numbers of jellyfish by using them for this purpose. But it is not all that simple; the slime is quite fragile, is difficult to freeze and defrost, and is therefore difficult to store. Consequently, at the moment it is not yet usable on a large-scale basis and studies are continuing.
* Chemistry of molecular and supramolecular systems for biomedical purposes
Decontamination of nanoparticles from aqueous samples using supramolecular gels
Amit Patwa, Jérôme Labille, Jean-Yves Bottero, Alain Thiéry and Philippe Barthélémy
Chem. Commun., 2015, 51, 2547-2550
Fluorescent dye infrared , cyanine derivative CyTE777
Name : CyTE777
Normalized spectra, excitation and emission of CyTE777. Measurements performed in water
Maximum of excitation is 777 nm and maximum of emission is 812 nm
In contrast to other cyanines, the CyTE777 don’t present aggregation problems in aqueous solutions
For your request please contact us : firstname.lastname@example.org ; tel 0033557571005
<!–more– Lire la suite>
<p”>Source : franceinfo.fr
Une équipe de chercheurs franco-belges s’est rendue compte que certaines zones du cerveau tentaient de s’autoréparer en cas de lésion. Les chercheurs ont donc eu l’idée de stimuler cette autoréparation. Pour cela, ils ont cultivé des cellules souches embryonnaires pour les transformer en cellules neuronales et ils les ont implantées dans le cortex de souris. Le cortex c’est la partie superficielle du cerveau où se traite la vision, l’audition, les mouvements…
Au bout d’un an, ils ont vu que la greffe avait été efficace sur 61 % des animaux, dont le cortex visuel s’était remis à fonctionner normalement. Chez les animaux où la greffe n’a pas bien fonctionné, des tumeurs sont apparues, ainsi que des amas de cellules non différenciées. “Notre approche est d’essayer de greffer des neurones en bonne santé pour remplacer la région du cerveau lésée. On appelle cela une thérapie cellulaire par transplantation,” explique Afsaneh Gaillard, professeur à l’université de Poitiers et responsable d’une équipe de recherche Inserm sur le cerveau qui a travaillé sur le projet.
Cette découverte peut permettre de rêver que l’on pourra un jour réparer le cerveau humain, remplacer les neurones qui sont abîmés par exemple par un AVC ou par la maladie comme Alzheimer ou celle de Parkinson. Mais attention à ne pas s’enflammer trop vite. “Plusieurs équipes dans le monde essaient de voir la possibilité de réparation dans différents types de lésions. On a montré, sur des animaux, qu’il est possible de réparer les lésions traumatiques, ou celles causées par la maladie de Parkinson. Ce sont des sujets de recherche en cours et les recherches essaient de voir la faisabilité de cette approche dans d’autres maladies,” précise Afsaneh Gaillard.
Les chercheurs n’ont pour le moment réalisé leurs tests que sur des souris. Rien ne dit que le succès de cette greffe sera identique chez l’homme. Ensuite, ce travail a montré que le cortex humain était encore plus compliqué que ce que l’on imaginait avec des centaines de types de neurones différents. Donc pour réparer une zone précise, il faut fabriquer les neurones correspondants. Pour faire simple on ne répare pas la zone du cortex responsable de la vision avec des neurones responsable des mouvements. “La difficulté est d’obtenir des neurones appropriés pour réparer le cortex visuel et voir la fonctionnalité des cellules à long terme et vérifier l’absence de formation de tumeur,” explique Afsaneh Gaillard. C’est une recherche expérimentale et il y a encore beaucoup de recherches à effectuer avant une application éventuelle chez l’homme, tempère Afsaneh Gaillard.